A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
← catalyst calendarSponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With ALX Oncology Inc..
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
52actual
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-15 | actual | When the study began enrolling |
| Primary completion | 2025-08-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-30 | actual | The whole study's end, after follow-up |
| First posted | 2021-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HER2-expressing Cancers
Interventions
- Drug: Zanidatamab — also filed as ZW25, JZP598, ZIIHERA®
- Drug: Evorpacept — also filed as ALX148
Primary outcomes
what the primary-completion date above is the date OFIncidence of dose-limiting toxicities (DLTs; Part 1)
measured Up to 4 weeks
Incidence of AEs (Part 1)
measured Up to 7 months
Incidence of clinical laboratory abnormalities (Part 1)
measured Up to 7 months
Confirmed objective response rate (ORR)(Part 2)
measured Up to 2 years
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed